Look at what all the partnerships have done for ARRY - absolutely nothing but give ARRY cash; in fact, I think all the partnerships have hurt ARRYs stock in terms of essentially wiping out any takeover premium.
I am glad Celldex is deciding to start a pivotal trial without a partner. They will be able to retain ownership of the asset, and also not get held back by some pharma that will likely move at stall speed, going through blue-ribbon multi-level executive meetings for a year deciding on how to run a trial.
Market Data 
Markets 
AI
